NeoPhore Ltd. logo

NeoPhore Ltd.

NeoPhore is a start-up biotech company targeting the dynamics of cancer neoantigen evolution and aims to make effective, well-tolerated small molecules that will become a key part of the next-generation of cancer immunotherapies.

NeoPhore is a spin-out from Cambridge-based PhoreMost Ltd, which collaborated with NeoPhores founders Professor Alberto Bardelli and Giovanni Germano to establish NeoPhores innovative approach.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.neophore.com
Founded2017
Disease Focus
Development Stage
STOCK CODENon Listed
Address
B580 Room 2011 Babraham Research Campus,Cambridge,CB22 3AT
Babraham,
United States
Email
Contact Number
+44 1223 804250

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/neophore-ltd” connections=”true” suffix=””]

NeoPhore is developing first-in-class small molecules DNA Mismatch Repair Inhibitors, that may result in production in creation of more neoantigen in cancer cells, thus marking them more vulnerable for attack by a patients own immune system. New (_neoÓ) antigens are abnormal proteins that typically arise from DNA mutations that accumulate during tumour formation.

In Nov 2017, NeoPhore received inital investment worth £3 Mn from Sixth Element Capital LLP, a UK based fund manager established to manage investments for the £70 Mn CRT Pioneer Fund.